Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel J Rader

Showing results (61-70 of 821) with videos related to

Pageof 83
Sort By:
Journal of the American College of Cardiology|July 27, 2019
Polygenic Risk Scores in Familial HypercholesterolemiaDaniel J Rader, Samip Sheth
Lancet (London, England)|April 9, 2013
Lipid-lowering treatment for homozygous familial hypercholesterolaemia--authors' replyMarina Cuchel, Daniel J Rader
Circulation Research|December 7, 2013
High-density lipoprotein: NO failure in heart failureAli Javaheri, Daniel J Rader
Journal of the American College of Cardiology|May 3, 2023
Lipoprotein(a) and Oxidized Phospholipids: Partners in Crime or Individual Perpetrators in Cardiovascular Disease?Daniel J Rader, Archna Bajaj
Cardiology Clinics|October 22, 2008
Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib?Hemanth Neeli, Daniel J Rader
JAMA Cardiology|October 29, 2025
Should Familial Hypercholesterolemia Be Included in Newborn Screening?Daniel J Rader, Sarah Schmidt
Current Atherosclerosis Reports|April 28, 2012
Sortilin as a regulator of lipoprotein metabolismAlanna Strong, Daniel J Rader
Clinical Chemistry|November 17, 2010
Phospholipidation of HDL--how much is too much?William R Lagor, Daniel J Rader
Cleveland Clinic Journal of Medicine|August 27, 2005
Demystifying triglycerides: a practical approach for the clinicianRichard L Dunbar, Daniel J Rader
Lancet (London, England)|August 19, 2014
HDL and cardiovascular diseaseDaniel J Rader, G Kees Hovingh
Pageof 83

Showing results (61-70 of 821) with videos related to

Sort By:
Pageof 83
Journal of the American College of Cardiology|July 27, 2019
Polygenic Risk Scores in Familial HypercholesterolemiaDaniel J Rader, Samip Sheth
Lancet (London, England)|April 9, 2013
Lipid-lowering treatment for homozygous familial hypercholesterolaemia--authors' replyMarina Cuchel, Daniel J Rader
Circulation Research|December 7, 2013
High-density lipoprotein: NO failure in heart failureAli Javaheri, Daniel J Rader
Journal of the American College of Cardiology|May 3, 2023
Lipoprotein(a) and Oxidized Phospholipids: Partners in Crime or Individual Perpetrators in Cardiovascular Disease?Daniel J Rader, Archna Bajaj
Cardiology Clinics|October 22, 2008
Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib?Hemanth Neeli, Daniel J Rader
JAMA Cardiology|October 29, 2025
Should Familial Hypercholesterolemia Be Included in Newborn Screening?Daniel J Rader, Sarah Schmidt
Current Atherosclerosis Reports|April 28, 2012
Sortilin as a regulator of lipoprotein metabolismAlanna Strong, Daniel J Rader
Clinical Chemistry|November 17, 2010
Phospholipidation of HDL--how much is too much?William R Lagor, Daniel J Rader
Cleveland Clinic Journal of Medicine|August 27, 2005
Demystifying triglycerides: a practical approach for the clinicianRichard L Dunbar, Daniel J Rader
Lancet (London, England)|August 19, 2014
HDL and cardiovascular diseaseDaniel J Rader, G Kees Hovingh
Pageof 83